At a glance
- Originator Bristol-Myers Squibb
- Class Anti-ischaemics; Antithrombotics
- Mechanism of Action Cyclic AMP phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Coronary thrombosis; Thrombosis